Abbonarsi

Metal- and redox homeostasis in prostate cancer with vitamin D3 supplementation - 11/07/18

Doi : 10.1016/j.biopha.2018.05.090 
Krisztina Süle a, b, , Klára Szentmihályi a , Gergő Szabó b , Dénes Kleiner b , Imre Varga c , Anna Egresi b , Zoltán May a , Péter Nyirády d , Miklós Mohai e , Anna Blázovics b
a Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Magyar Tudósok körútja 2, H-1117 Budapest, Hungary 
b Institute of Farmacognosy Semmelweis University, Üllői út 26, H-1086 Budapest, Hungary 
c Medical Center of Dunakeszi, Fő út 75-86, H-2120 Dunakeszi, Hungary 
d Department of Urology and Urooncological Centre, Semmelweis University, Üllői út 78/b, H-1082 Budapest, Hungary 
e Budapest University of Technology and Economics, Műegyetem rkp. 3, H-.1111 Budapest, Hungary 

Corresponding author at: Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Magyar Tudósok körútja 2, H-1117 Budapest, Hungary.Institute of Materials and Environmental ChemistryResearch Centre for Natural Sciences of the Hungarian Academy of SciencesMagyar Tudósok körútja 2BudapestH-1117Hungary

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 8
Iconografia 1
Video 0
Altro 0

Graphical abstract

*significant difference to the patient control (A) p < 0.01.

**significant difference to the high risk prostate cancer without vitamin D3 treatment (C) p<0.01.

Abbreviations: A, patient control; B, patient control with vitamin D3 treatment; C, high-risk prostate cancer group; D, high-risk prostate cancer group with vitamin D3 treatment; E, vitamin D3 treated cancerous group with androgen deprivation therapy.




Il testo completo di questo articolo è disponibile in PDF.

Highlights

Vitamin D3 treatment was applied for patient controls and prostate cancerous patients with different states.
Vitamin D3 treatment had an effect on PSA level.
Vitamin D3 treatment helped to equilibrate the redox homeostasis.
Vitamin D3 treatment influenced on the metal element homeostasis, especially in the cases of Ca, Cr, Cu, Fe, Li and Pb.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Vitamin D3 supplementation has a beneficial effect on cancerous patients, although it can influence the redox- and metal homeostasis. The aim of our investigation was to demonstrate the effect of vitamin D3 consumption on the redox- and metal homeostasis in prostate cancer, because of the recommended daily dose increased from 200 IU to 2000 IU in recent years in Hungary. Forty-three volunteers were involved in the study. The grouping was applied according to the clinical routine laboratory parameters (vitamin D3) and the tumor markers (PSA, fPFA). Patients were divided into 5 groups: (A) patient control (N = 8), (B) patient control with vitamin D3 treatment (N = 9), (C) high-risk prostate cancer group (N = 6), (D) high-risk prostate cancer group with vitamin D3 treatment (N = 8) and (E) vitamin D3 treated cancerous group with androgen deprivation therapy (N = 11). The element concentrations were determined with ICP-OES. Among the redox parameters, free radical scavenging capacity and H-donating ability were determined with luminometry and spectrometry. Vitamin D3 treatment caused differences in the metal- and redox homeostasis in either patient control and cancerous groups. The concentration of Fe, Cr, and Pb significantly increased in the erythrocytes of prostate cancer patients. According to the higher scavenging capacity by vitamin D3 treatment, it seems that vitamin D3 helps to equilibrate the redox homeostasis that could affect the outcome of cancer positively. However, the tendency in the metal element status does not give a clear explanation of cancer's outcome, but the accumulation of Pb by vitamin D3 supplementation needs to be taken into more serious consideration in set terms of occupational diseases.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : Al, ALT, AP-1, AR, AST, B, Ba, BMI, Ca, CDK4, CEA, Chol, CHR, CKI, Co, Cr, CREA, CRP, Cu, DNA, DV, EGF, Fe, fPSA, G1, G2, GADD45α, GGT, GOT, GPT, GSK-3, H2O2, HCHO, HCl, HGB, HIF-1, HNO3, ICP-OES, IKEB, IL-2, -6, -10, INK4, IU, LDH, Li, LMWCr, M, MCV, Mg, Mn, MV, NADH, NFAT, NF-κB, Ni, P, p21waf1, p27kip1, p53, Pb, PDGF, PSA, R, RLU, RNA, RXR, S, Sr, Ti, TNF-α, TSC, TUKEB, UA, V, VDR, VEGF, WBC, Zn

Keywords : Micro-macro elements, prostate cancer, vitamin D3, ICP-OES


Mappa


© 2018  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 105

P. 558-565 - settembre 2018 Ritorno al numero
Articolo precedente Articolo precedente
  • Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2
  • Kejian Zhang, Mingrui Zhang, Hui Jiang, Fenglin Liu, Hongwei Liu, Yang Li
| Articolo seguente Articolo seguente
  • ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment
  • Li Pan, Hongli Yang, Cong Xu, Shuangfeng Chen, Zhen Meng, Keyi Li, Haiying Chen

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.